RedHill Biopharma’s Opaganib Inhibits COVID-19 Variants in Preclinical Study
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib’s unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect against other emerging variants, including the Delta (Indian) variant Completion of opaganib’s global fully enrolled 475-patient Phase 2/3…